T1	Premise 1318 1418	The combination arm was more effective than arm 2 with respect to LBM, REE, fatigue, and global QoL.
T2	Premise 1419 1537	As for the secondary efficacy endpoints, patient appetite increased, and ECOG PS decreased significantly in both arms.
T3	Premise 1538 1697	The inflammation and oxidative stress parameters IL-6, TNF-Î±, CRP, and ROS decreased significantly in arm 1, while no significant change was observed in arm 2.
T4	Claim 1698 1779	The combined treatment improved both immunometabolic alterations and patient QoL.
T5	MajorClaim 1780 1966	Multimodality therapies for cachexia ideally should be introduced within a context of "best supportive care" that includes optimal symptom management and careful psychosocial counseling.
R1	Support Arg1:T1 Arg2:T4	
R2	Support Arg1:T2 Arg2:T4	
R3	Support Arg1:T3 Arg2:T4	
